Institutional members access full text with Ovid®

MACULAR SENSITIVITY AND MORPHOLOGY AFTER INTRAVITREAL INJECTION OF TRIAMCINOLONE ACETONIDE FOR MACULAR EDEMA WITH BRANCH RETINAL VEIN OCCLUSION

Noma, Hidetaka MD*; Funatsu, Hideharu MD*; Mimura, Tatsuya MD; Shimada, Katsunori PhD

doi: 10.1097/IAE.0b013e318259569f
Original Study

Purpose: To evaluate the changes of macular sensitivity, thickness, and total macular volume after intravitreal injection of triamcinolone acetonide to treat macular edema with branch retinal vein occlusion.

Methods: Seventeen eyes of 17 patients with branch retinal vein occlusion with macular edema received intravitreal triamcinolone acetonide. Using capillary nonperfusion on fluorescein angiography, patients were classified into nonischemic or ischemic groups. Microperimetry was used to measure macular sensitivity within the central 4°, 10°, and 20° fields. Macular thickness and macular volume within these fields were measured by optical coherence tomography.

Results: The mean macular thickness within the central 4°, 10°, and 20° fields decreased significantly after intravitreal therapy (all Ps < 0.001) as did total macular volume (all Ps < 0.001). Visual acuity was significantly better at 3 and 6 months (P = 0.002) as was the mean macular sensitivity within the three fields (all Ps < 0.05). There were no significant differences in the trend profile of macular thickness and volume within the three fields between the ischemic and nonischemic groups. There were also no significant differences in the trend profile of visual acuity and macular sensitivity.

Conclusion: Intravitreal triamcinolone acetonide may improve macular sensitivity and morphology in patients with ischemic and nonischemic branch retinal vein occlusion.

In patients with branch retinal vein occlusion and macular edema, visual acuity, macular sensitivity, mean macular thickness, and total macular volume were significantly improved at 3 and 6 months after intravitreal injection of triamcinolone acetonide. Thus, intravitreal triamcinolone acetonide may improve both macular sensitivity and morphology in such patients.

*Department of Ophthalmology, Yachiyo Medical Center, Tokyo Women's Medical University, Owada-shinden, Yachiyo, Chiba, Japan

Department of Ophthalmology, University of Tokyo Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan

Department of Hygiene and Public Health II, Tokyo Women's Medical University, Kawada-cho, Shinjiku-ku, Tokyo, Japan.

Reprint requests: Hidetaka Noma, MD, Department of Ophthalmology, Yachiyo Medical Center, Tokyo Women's Medical University, 477-96, Owada-shinden, Yachiyo, Chiba 276-8524, Japan; e-mail: noma-hide@umin.ac.jp

The authors have no financial or conflicts of interest to disclose.

© The Ophthalmic Communications Society, Inc.